


| Key | % Net Assets |
|---|---|
| 8.1% | |
| 7.6% | |
| 5.8% | |
| 5.1% | |
| 73.4% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 8.1% |
| AstraZeneca | 7.6% |
| GlaxoSmithKline | 5.8% |
| Roche | 5.1% |
| BT | 5.1% |
| Reynolds American | 4.8% |
| Vodafone | 4.8% |
| BG | 4.5% |
| Reckitt Benckiser | 4.5% |
| Imperial Tobacco | 4.2% |
No asset data available.
| Date | 20-Aug-2025 |
|---|---|
| NAV | 3,623.44p |
| Currency | GBP |
| Change | 5.58p |
| % | 0.15% |
| YTD change | 405.31p |
| YTD % | 12.59% |
| Fund Inception | 16/06/1979 |
|---|---|
| Fund Manager | Neil Woodford |
| TER | 1.69 (31-Dec-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | £100 |
| Savings | £20 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.66% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.21 |
You are here: research